BioMarin Boosts 2026 Revenue Guidance After Amicus Acquisition
Event summary
- BioMarin raised its full-year 2026 revenue guidance to $3.825-$3.925 billion, up from $3.325-$3.425 billion, following the Amicus acquisition.
- First-quarter 2026 revenues increased 3% year-over-year to $766 million, driven by Enzyme Therapies and VOXZOGO demand.
- GAAP net income decreased 43% year-over-year to $106 million due to higher operating expenses related to the Amicus acquisition.
- BioMarin expects two near-term Phase 3 data readouts and ongoing pipeline progress in the coming quarters.
The big picture
BioMarin's acquisition of Amicus Therapeutics marks a strategic pivot to accelerate growth in rare disease treatments. The addition of GALAFOLD and POMBILITI + OPFOLDA to its portfolio strengthens its position in Fabry and Pompe diseases, while the company's pipeline progress and regulatory milestones will be key to sustaining its momentum. The integration of Amicus and the company's ability to manage higher operating expenses will be critical to its financial performance in 2026.
What we're watching
- Integration Success
- How BioMarin will leverage its global scale to expand the potential of Amicus's transformative therapies.
- Regulatory Milestones
- The pace at which BioMarin can secure approvals for its pipeline candidates, including BMN 401 and VOXZOGO for hypochondroplasia.
- Financial Performance
- Whether BioMarin can sustain its accelerated growth rate and improve profitability amid higher operating expenses.
Related topics